Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gómez-Hospital, J. A.
Right arrow Articles by Esplugas, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gómez-Hospital, J. A.
Right arrow Articles by Esplugas, E.
(Chest. 2005;127:40-46.)
© 2005 American College of Chest Physicians

Persistence of Lung Function Abnormalities Despite Sustained Success of Percutaneous Mitral Valvotomy*

The Need for an Early Indication

Joan A. Gómez-Hospital, PhD; Angel Cequier, PhD; Pablo V. Romero, MD; Concepción Cañete, MD; Carmen Ugartemendia, MD; Emili Iràculis, PhD and Enrique Esplugas, PhD

* From the Divisions of Cardiology (Drs. Gómez-Hospital, Cequier, Ugartemendia, Iràculis, and Esplugas) and Pulmonary Diseases (Drs. Romero and Cañete), Hospital de Bellvitge, University of Barcelona, Barcelona, Spain.

Correspondence to: Joan A. Gómez-Hospital, PhD, Cardiac Catheterization Laboratory, Hospital of Bellvitge, C/ Feixa Llarga s/n, Hospitalet del Llobregat, 08907 Barcelona, Spain; e-mail: 26587jgh{at}comb.es

Aims: We assessed early and long-term pulmonary function changes after percutaneous balloon mitral valvotomy (PBMV).

Methods and results: Mitral area, lung function, and exercise capacity were evaluated before, immediately after, and 3 months, 6 months, and 12 months after successful PBMV in 24 patients. PBMV resulted in a significant and sustained increase in mitral area, from 1.0 ± 0.1 to 1.9 ± 0.1 cm2 (p = 0.001) [mean ± SD], with a progressive increase in exercise tolerance at 6-month follow-up (from 22.6 ± 1.4 to 28.2 ± 1.2 mL/kg, p = 0.0001). An immediate drop in the diffusing capacity of the lung for carbon monoxide (DLCO) was observed (from 26.7 ± 1.5 to 22.3 ± 1.1 mL/min/mm Hg, p = 0.0002) after PBMV, followed by a gradual regression to baseline values at 3 months; at 1 year, the DLCO remained elevated (27.3 ± 6.3 mL/min/mm Hg). The flow in the small airways was reduced at baseline, and there was no significant change during follow-up.

Conclusions: PBMV produces an initial decrease in DLCO, suggesting a reduction of pulmonary congestion. During follow-up, the regression to the initial lung diffusion values despite a sustained hemodynamic improvement suggests that some irreversible interstitial changes were present. In patients with mitral stenosis, an impairment of lung function parameters suggests that PBMV must be performed early, even if patients have few symptoms.

Key Words: exercise capacity • mitral stenosis • percutaneous balloon mitral valvotomy • pulmonary function






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Chest Physicians.